Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

NCT00959959 is registered in ClinicalTrials.gov with LTN PHARMACEUTICALS, INC. as lead sponsor.

NCT NCT00959959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Lead sponsor
LTN PHARMACEUTICALS, INC.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2009
Completion date
August 31, 2012
Enrollment
49 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer